Table 3.
Adverse events of 62 Chinese patients with advanced NSCLC and 2nd-line chemotherapy of nintedanib
| Adverse Events | Grade 1 or 2 | Grade 3 or 4 | ||
|---|---|---|---|---|
|
| ||||
| Number | Percentage | Number | Percentage | |
| Diarrhea | 44 | 71.0% | 6 | 9.8% |
| Nausea | 26 | 43.5% | 4 | 6.5% |
| Chest pain | 17 | 27.4% | 3 | 4.8% |
| Fatigue | 10 | 16.1% | 2 | 3.2% |
| Nausea | 13 | 21.0% | 2 | 3.2% |
| Asthenia | 8 | 12.9% | 0 | 0% |
| Pneumonia | 9 | 14.5% | 5 | 8.1% |
| Hypertension | 13 | 21.0% | 7 | 11.3% |
| Vomiting | 7 | 11.3% | 3 | 4.8% |
| Hyperglycaemia | 8 | 12.9% | 1 | 1.6% |
| Bleeding | 6 | 9.7% | 1 | 1.6% |
| Anemia | 4 | 6.5% | 2 | 3.2% |
| Heart failure | 31 | 50.0% | 12 | 19.4% |